Rely on a single comprehensive genomic profile to optimize overall breast cancer treatment strategy.
Please log in for more information
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
Agendia is a leading molecular diagnostics company focused on improving the quality of life for cancer patients by developing genomic tests to support physicians in making complex treatment decisions while reducing costs to the healthcare system. Our genomic tests are helping to achieve this goal with global guideline inclusion, as well as a growing customer base, including many major hospitals and clinical institutions. MammaPrint, our FDA-cleared test backed by the highest level of clinical evidence, paired with BluePrint, the only commercially available molecular subtyping test, enable physicians to confidently optimize a unique treatment strategy for each patient.